[{"id":"92b543b8-0666-45b8-8525-786af02d2693","acronym":"","url":"https://clinicaltrials.gov/study/NCT04418167","created_at":"2021-01-18T21:17:40.725Z","updated_at":"2024-07-02T16:35:20.996Z","phase":"Phase 1","brief_title":"JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations","source_id_and_acronym":"NCT04418167","lead_sponsor":"JS InnoPharm, LLC","biomarkers":" MAP2K1 • NF1 • RASA1","pipe":" | ","alterations":" BRAF V600E • BRAF V600K","tags":["MAP2K1 • NF1 • RASA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tafinlar (dabrafenib) • JSI-1187"],"overall_status":"Suspended","enrollment":" Enrollment 71","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/17/2024","study_completion_date":" 12/17/2024","last_update_posted":"2024-02-02"}]